ClinicalTrials.gg
Active, not recruitingNCT06212583KNIGHTSUpdated May 6, 2026

High-Risk Metachronous Oligometastatic Prostate Cancer Trial

A Phase 2 interventional study of niraparib/abiraterone acetate and Stereotactic ablative radiation therapy (SABR) in Prostate Cancer and Oligometastatic Disease, sponsored by University of Maryland, Baltimore. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-06.

Sponsored by University of Maryland, Baltimore · Phase 2, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore — 1 open to participants now, 4 under way, none of them phase 3. Prostatic Neoplasms · University of Maryland, Baltimore.

Planned enrollment
2nd of 10
88 · median 27
Started
2024
with 1 other
Phase 2
8 of 14
1 open now
Registered
14th of 14
by date

Among the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, this one is the 2nd largest by planned enrollment of the 10 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 2, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

1 of the 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Prostatic Neoplasms by University of Maryland, Baltimore, or all of them as a file.
02

Study summary

The purpose of this research study is to compare the effects, good and/or bad, of using the standard of care treatment, hormonal therapy + Stereotactic Ablative Radiation (SABR) to the metastatic lesions, compared to standard of care and addition of 6-months of niraparib/abiraterone acetate combination pills and prednisone for participants with recurrent metastatic prostate cancer.

Read the detailed description

In this trial all participants will be randomized to one of the two groups. You will be randomly assigned (by chance, like the flip of a coin) to one of the two groups: 1: Standard of care treatment (hormonal therapy + SABR to the metastatic lesions) or 2: Standard of care treatment + 6-months of niraparib/abiraterone acetate combination pills and prednisone. Participants in both groups will receive rectal swabs and various blood tests to assess circulating tumor cells, genomic sequencing, and tumor markers. Both groups will also participate in quality-of-life surveys

03

Conditions studied

  • Prostate Cancer
  • Oligometastatic Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. ≥18 years of age (or the local legal age of consent).
  2. Patient must have at least one and up to three asymptomatic tumor(s) of the bone, soft tissue, or extra-pelvic nodal region each \< 5 cm or \< 250 cm3 that develop within the past 6-months that are seen on imaging. A nodal lesion is defined to include nodal conglomerates located in the same nodal chain such that they can be treated in one SABR field. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or Prostate Specific Membrane Antigen (PSMA) PET-CT scan.

    1. CT or MRI scan within 6 months of enrollment
    2. Bone scan within 6 months of enrollment
    3. Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
  3. Must have a high-risk pathogenic mutation (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) by next generation sequencing. ATM mutation enrollment will be capped at 5% of the overall population.
  4. Histologic confirmation of prostate adenocarcinoma (primary or metastatic tumor).
  5. Patient may have had prior systemic therapy and/or ADT so long as testosterone is > 100 ng/dl prior to enrollment
  6. PSA > 0.5 but \<50 at enrollment.
  7. Prostate Specific Antigen Doubling Time (PSADT) \< 15 months
  8. Baseline testosterone > 100 ng/dl
  9. Patient must have a ≥ 12 months.
  10. Patient must have an performance status ≤ 2.
  11. Adequate hematologic, renal, and hepatic function at screening defined as follows:

    • ≥1.5 x 109/L
    • ≥9.0 g/dL, independent of transfusions for at least 28 days
    • count ≥100 x 109/L
    • Creatinine \<2 x (ULN)
    • Serum potassium ≥3.5 mmol/L
    • Serum total ≤1.5× ULN or direct bilirubin ≤1 x ULN (Note: In participants with Gilbert's syndrome, if total bilirubin is >1.5 × ULN, measure direct and indirect bilirubin, and if direct bilirubin is ≤1.5 × ULN, participant may be eligible)
    • or ALT ≤3 × ULN
  12. Patient must have the ability to understand and the willingness to sign a written document
  13. Able to swallow the study medication tablets whole.
  14. While on study medication and for 4 months following the last dose of study medication, a male participant must agree to use condom and an adequate method for female partner () A male participant must agree not to donate sperm while on study treatment and for a minimum of 4 months following the last dose of study medication.

<!-- -->

  1. Castration-resistant prostate cancer (CRPC).
  2. Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
  3. Spinal cord compression or impending spinal cord compression.
  4. Suspected intracranial and/or liver metastases (>10 mm in largest axis).
  5. Patient receiving any other agents.
  6. Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist.
  7. Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
  8. Radiographical evidence of cranial parenchymal metastasis.
  9. Active second primary ; AML/MDS in medical history.
  10. Uncontrolled hypertension and myocardial infarction/PE/cardiac failure in last 6 months.
  11. Prior treatment with PARP inhibitor
  12. Refusal to sign informed consent.
  13. Pathological finding consistent with small cell or neuroendocrine carcinoma of the prostate.
  14. History of adrenal dysfunction
  15. Long-term use of systemically administered (>5mg of prednisone or the equivalent) during the study is not allowed. Short-term use (≤4 weeks, including taper) and locally administered steroids (eg, inhaled, topical, ophthalmic, and intra-articular) are allowed, if clinically indicated.
  16. Active malignancies (ie, progressing or requiring treatment change in the last 24 months) other than the disease being treated under study. The only allowed exceptions are:

    • non-muscle invasive bladder cancer.
    • skin cancer (non-melanoma or melanoma) treated within the last 24 months that is considered completely cured.
    • malignancy that is considered cured with minimal risk of recurrence.
    • History or current diagnosis of MDS/AML.
  17. Current evidence within 6 months prior to randomization of any of the following:

    • severe/unstable angina, myocardial infarction, symptomatic congestive heart failure,
    • arterial or venous thromboembolic events (ie. Pulmonary embolism), or clinically significant ventricular arrhythmias.
  18. Presence of sustained uncontrolled hypertension (systolic blood pressure >160 mm Hg or diastolic blood pressure >100 mm Hg). Participants with a history of hypertension are allowed, provided that blood pressure is controlled to within these limits by an antihypertensive treatment.
  19. Known allergies, , or intolerance to the of niraparib/abiraterone acetate tablets
  20. Current evidence of any medical condition that would make prednisone use .
  21. Received an investigational intervention (including investigational vaccines) or used an invasive investigational medical device within 30 days before the planned first dose of study medication.
  22. Participants who have had the following ≤28 days prior to randomization:

    • A transfusion (platelets or red blood cells);
    • Hematopoietic growth factors;
    • Major surgery
  23. positive participants with 1 or more of the following:

    • Not receiving highly active antiretroviral therapy or on antiretroviral therapy for less than 4 weeks.
    • Receiving antiretroviral therapy that may interfere with the study medication
    • \<350 at screening.
    • An acquired immunodeficiency syndrome-defining opportunistic infection within 6 months of the start of screening.
    • Human immunodeficiency virus load >400 copies/mL
  24. Active or symptomatic viral hepatitis or chronic liver disease; encephalopathy, ascites or bleeding disorders secondary to hepatic dysfunction.
  25. Moderate or severe hepatic impairment (Class B and C per classification system.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
88 participants (estimated)

Study arms

  • Active comparator
    Androgen deprivation therapy + Stereotactic ablative radiation

    Radiation: Stereotactic ablative radiation therapy (SABR) · Drug: Androgen deprivation therapy (ADT)

  • Active comparator
    Androgen deprivation therapy + Stereotactic ablative radiation + niraparib/abiraterone acetate

    Drug: niraparib/abiraterone acetate · Radiation: Stereotactic ablative radiation therapy (SABR) · Drug: Androgen deprivation therapy (ADT)

Interventions

  • Drugniraparib/abiraterone acetate

    Drug page: Abiraterone Acetate/NiraparibStudies of Abiraterone Acetate/NiraparibAbiraterone Acetate/Niraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients on Arm 2 to receive drug for 6 months

  • RadiationStereotactic ablative radiation therapy (SABR)

    Both arms will receive SABR

  • DrugAndrogen deprivation therapy (ADT)

    All ADT is provided as best prescribed for patient per their medical oncologist.

This study also gives NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. PSA (Prostate Specific Antigen) evaluation at the 18-month progression of both treatment arms

    PSA evaluation of progression at 18-month PSA , defined as PSA \> 0.2 ng/mL in patients initially treated with radical prostatectomy and greater than nadir + 2 ng/mL for patients initially treated with definitive radiation, with testosterone \>100 ng/dl of men who have oligometastatic castration-sensitive prostate cancer with high-risk mutations (TP53, BRCA1/2, PALB2, ATM, BRIP1, CHEK2, FANCA, RAD51B, RAD54L, MUTYH) treated with ADT + SABR MDT (6-mos) versus ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).

    Time frame: 18 months

Secondary outcomes

  1. Treatment-related adverse events of both treatment arms

    Number of participants with treatment-related adverse events from ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic CSPC disease.

    Time frame: 4 years

  2. Local control at 18 months after ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos) in patients with metachronous oligometastatic Castrate Specific Prostate Cancer (CSPC) disease.

    Local control will be evaluated through clinical assessment and periodic imaging.

    Time frame: 18 months

  3. Time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization

    Progression will be assessed for time to locoregional progression, time to distant progression, time to new metastasis, radiographic progression-free survival and duration of response after randomization.

    Time frame: 4 years

  4. Quality-of-life measured through EPIC tool following completion of ADT+ SABR MDT (6-mos) vs ADT + SABR MDT + niraparib/abiraterone acetate and prednisone (6-mos).

    EPIC quality of life tool will be used to assess quality of life following treatment. Averages will be taken for each section in the survey (Urinary Function, Bowel Function, Sexual Function, and Hormonal function).

    Time frame: 4 years

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Dec 2028, 56 months after the start.

Of 613 non-industry phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 86. This study's planned 56 months is close to that.

Counting every sponsor, half of 727 studies reached it within 53 months; a quarter within 34 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2023
First posted
Jan 19, 2024
StartActual
Apr 17, 2024
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
May 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06212583
Responsible party
Jason Molitoris, MD PhD (Principal Investigator, University of Maryland, Baltimore) — Principal investigator
First posted
Jan 19, 2024
Start date
Apr 17, 2024
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
May 6, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abiraterone Acetate/Niraparib · Niraparib

Start the discussion